Price T Rowe Associates Inc. MD Sells 452,549 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Price T Rowe Associates Inc. MD lowered its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 43.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 589,906 shares of the biopharmaceutical company’s stock after selling 452,549 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.55% of Intra-Cellular Therapies worth $49,270,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Norges Bank acquired a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $268,347,000. Raymond James Financial Inc. acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth $76,451,000. TimesSquare Capital Management LLC lifted its position in Intra-Cellular Therapies by 91.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock valued at $70,179,000 after acquiring an additional 402,186 shares in the last quarter. Franklin Resources Inc. boosted its stake in Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock worth $129,463,000 after purchasing an additional 155,655 shares during the period. Finally, Walleye Capital LLC increased its holdings in Intra-Cellular Therapies by 49.5% during the 4th quarter. Walleye Capital LLC now owns 383,591 shares of the biopharmaceutical company’s stock worth $32,038,000 after purchasing an additional 127,003 shares in the last quarter. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ ITCI opened at $131.87 on Wednesday. The business’s 50 day moving average price is $131.29 and its two-hundred day moving average price is $109.06. The company has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. As a group, research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Analyst Ratings Changes

ITCI has been the subject of several recent research reports. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their price target for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Royal Bank of Canada reissued a “sector perform” rating and issued a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Finally, Baird R W cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Eleven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus price target of $109.70.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.